Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS
Author(s) -
Amaya Rando,
Miriam de la Torre,
Anna MartínezMuriana,
P. Zaragoza,
Antonio Musarò,
Sara Hernández,
Xavier Navarro,
Janne M. Toivonen,
Rosario Osta
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0210752
Subject(s) - amyotrophic lateral sclerosis , antimetabolite , drug , medicine , sod1 , fluorouracil , motor neuron , pharmacology , mitoxantrone , drug repositioning , disease , cancer , chemotherapy
Amyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease with no cure. Currently there are only two ALS drugs approved by the FDA, both with a limited therapeutic effect. In the search for drug candidates for ALS, we studied the effect of known stem cell mobilizing agents (treatment) and antimetabolite 5-fluorouracil (5-FU) (anti-treatment) in SOD1G93A model of ALS. Surprisingly, we found that anti-cancer drug 5-FU increases lifespan, delays the disease onset and improves motor performance in ALS mice. Although we were not able to demonstrate the mechanistic basis of the beneficial 5-FU action in ALS mice, our findings suggest that 5-FU or similar drugs are possible drug candidates for the treatment of motor neuron diseases through drug repurposing.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom